Jump to content

Oculocerebrorenal syndrome: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Monkbot (talk | contribs)
m Task 18 (cosmetic): eval 15 templates: del empty params (2×); hyphenate params (8×);
Citation bot (talk | contribs)
Add: doi-access. | Use this bot. Report bugs. | Suggested by Abductive | Category:Syndromes affecting the kidneys | #UCB_Category 41/42
 
(9 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{Infobox medical condition (new)
{{Infobox medical condition (new)
| name = Oculocerebrorenal syndrome
| name = Oculocerebrorenal syndrome
| synonyms = Lowe syndrome
| synonyms = Lowe syndrome
| image = File:X-linked recessive.svg
| image = Oculo-Cerebro-Renal Syndrome 2.jpg
| caption = Oculocerebrorenal syndrome is [[X-linked recessive]].
| caption = Infant with oculocerebrorenal syndrome
| pronounce =
| pronounce =
| field =
| field =
| symptoms = Cataracts<ref name=emed/>
| symptoms = Cataracts<ref name=emed/>
| complications =
| complications =
| onset =
| onset =
| duration =
| duration =
| types =
| causes = Mutations in ''[[OCRL]] ''gene<ref name=emed/>
| types =
| risks =
| causes = Mutations in ''[[OCRL]] ''gene<ref name=emed/>
| diagnosis = MRI, [[urinalysis]]<ref name=lowe/>
| risks =
| differential =
| diagnosis = MRI, [[urinalysis]]<ref name=lowe/>
| differential =
| prevention =
| treatment = Physical therapy, [[clomipramine]]<ref name=orp/>
| prevention =
| medication =
| treatment = Physical therapy, [[clomipramine]]<ref name=orp/>
| medication =
| prognosis =
| prognosis =
| frequency =
| frequency =
| deaths =
| deaths =
}}
}}
'''Oculocerebrorenal syndrome''' (also called '''Lowe syndrome''') is a rare [[X-linked]] recessive disorder characterized by congenital cataracts, [[hypotonia]], [[intellectual disability]], [[proximal tubular]] [[acidosis]], [[aminoaciduria]] and low-molecular-weight [[proteinuria]]. Lowe syndrome can be considered a cause of [[Fanconi syndrome]] (bicarbonaturia, renal tubular acidosis, [[potassium]] loss and [[sodium]] loss<ref>{{Cite web|url=https://medlineplus.gov/ency/article/000333.htm|title=Fanconi syndrome: MedlinePlus Medical Encyclopedia|website=medlineplus.gov|access-date=2016-12-21}}</ref>).<ref>{{Cite book|chapter-url=https://www.ncbi.nlm.nih.gov/books/NBK1480/|title=GeneReviews|last1=Lewis|first1=Richard Alan|last2=Nussbaum|first2=Robert L.|last3=Brewer|first3=Eileen D.|date=1993-01-01|publisher=University of Washington, Seattle|editor-last=Pagon|editor-first=Roberta A.|location=Seattle (WA)|pmid=20301653|editor-last2=Adam|editor-first2=Margaret P.|editor-last3=Ardinger|editor-first3=Holly H.|editor-last4=Wallace|editor-first4=Stephanie E.|editor-last5=Amemiya|editor-first5=Anne|editor-last6=Bean|editor-first6=Lora JH|editor-last7=Bird|editor-first7=Thomas D.|editor-last8=Fong|editor-first8=Chin-To|editor-last9=Mefford|editor-first9=Heather C.|chapter=Lowe Syndrome}}update 2012</ref><ref>{{cite web|title=OMIM Entry - # 309000 - LOWE OCULOCEREBRORENAL SYNDROME; OCRL|url=https://omim.org/entry/309000|website=omim.org|access-date=21 December 2016}}</ref>
'''Oculocerebrorenal syndrome''' (also called '''Lowe syndrome''') is a rare [[X-linked]] recessive disorder characterized by congenital cataracts, [[hypotonia]], [[intellectual disability]], [[proximal tubular]] [[acidosis]], [[aminoaciduria]] and low-molecular-weight [[proteinuria]]. Lowe syndrome can be considered a cause of [[Fanconi syndrome]] (bicarbonaturia, renal tubular acidosis, [[potassium]] loss and [[sodium]] loss<ref>{{Cite web|url=https://medlineplus.gov/ency/article/000333.htm|title=Fanconi syndrome: MedlinePlus Medical Encyclopedia|website=medlineplus.gov|access-date=2016-12-21}}</ref>).<ref>{{Cite book|chapter-url=https://www.ncbi.nlm.nih.gov/books/NBK1480/|title=GeneReviews|last1=Lewis|first1=Richard Alan|last2=Nussbaum|first2=Robert L.|last3=Brewer|first3=Eileen D.|date=1993-01-01|publisher=University of Washington, Seattle|editor-last=Pagon|editor-first=Roberta A.|location=Seattle (WA)|pmid=20301653|editor-last2=Adam|editor-first2=Margaret P.|editor-last3=Ardinger|editor-first3=Holly H.|editor-last4=Wallace|editor-first4=Stephanie E.|editor-last5=Amemiya|editor-first5=Anne|editor-last6=Bean|editor-first6=Lora J.H.|editor-last7=Bird|editor-first7=Thomas D.|editor-last8=Fong|editor-first8=Chin-To|editor-last9=Mefford|editor-first9=Heather C.|chapter=Lowe Syndrome}}update 2012</ref><ref>{{cite web|title=OMIM Entry - # 309000 - LOWE OCULOCEREBRORENAL SYNDROME; OCRL|url=https://omim.org/entry/309000|website=omim.org|access-date=21 December 2016}}</ref>


==Signs and symptoms==
==Signs and symptoms==
Line 28: Line 28:


==Genetics==
==Genetics==
[[File:NIH 3T3.jpg|thumb|120 px|left|[[Fibroblasts]]]]
This syndrome is caused by mutations in the ''[[OCRL]]'' gene which encodes an [[inositol polyphosphate-5-phosphatase]]. At least one mechanism by which these mutations cause this syndrome is by loss of its [[Rab (G-protein)|Rab]]-binding [[Protein domain|domain]].<ref>{{Cite journal|last1=Hagemann|first1=Nina|last2=Hou|first2=Xiaomin|last3=Goody|first3=Roger S.|last4=Itzen|first4=Aymelt|last5=Erdmann|first5=Kai S.|date=2017-06-01|title=Crystal structure of the Rab binding domain of OCRL1 in complex with Rab8 and functional implications of the OCRL1/Rab8 module for Lowe syndrome|journal=Small GTPases|volume=3|issue=2|pages=107–110|doi=10.4161/sgtp.19380|issn=2154-1256|pmid=22790198|doi-access=free}}</ref><ref name="nih">{{cite web|last1=Reference|first1=Genetics Home|title=Lowe syndrome|url=https://ghr.nlm.nih.gov/condition/lowe-syndrome|website=Genetics Home Reference|access-date=21 December 2016}}</ref>
This syndrome is caused by mutations in the ''[[OCRL]]'' gene which encodes an [[inositol polyphosphate-5-phosphatase]]. At least one mechanism by which these mutations cause this syndrome is by loss of its [[Rab (G-protein)|Rab]]-binding [[Protein domain|domain]].<ref>{{Cite journal|last1=Hagemann|first1=Nina|last2=Hou|first2=Xiaomin|last3=Goody|first3=Roger S.|last4=Itzen|first4=Aymelt|last5=Erdmann|first5=Kai S.|date=2017-06-01|title=Crystal structure of the Rab binding domain of OCRL1 in complex with Rab8 and functional implications of the OCRL1/Rab8 module for Lowe syndrome|journal=Small GTPases|volume=3|issue=2|pages=107–110|doi=10.4161/sgtp.19380|issn=2154-1256|pmid=22790198|doi-access=free}}</ref><ref name="nih">{{cite web|last1=Reference|first1=Genetics Home|title=Lowe syndrome|url=https://ghr.nlm.nih.gov/condition/lowe-syndrome|website=Genetics Home Reference|access-date=21 December 2016}}</ref>


This protein is associated with the primary [[cilia]] of the [[retinal pigment epithelial]] cells, [[fibroblast]]s and kidney [[Nephron|tubular]] cells. This suggests that this syndrome is due to dysfunction of the cilia in these cells.<ref name=nih/> About 120 mutations are associated with this condition and ''OCRL'' gene which is associated with oculocerebrorenal syndrome<ref>{{cite web|last1=Reference|first1=Genetics Home|title=OCRL gene|url=https://ghr.nlm.nih.gov/gene/OCRL#conditions|website=Genetics Home Reference|access-date=21 December 2016}}</ref>
This protein is associated with the primary [[cilia]] of the [[retinal pigment epithelial]] cells, [[fibroblast]]s and kidney [[Nephron|tubular]] cells. This suggests that this syndrome is due to dysfunction of the cilia in these cells.<ref name=nih/> About 120 mutations are associated with this condition and ''OCRL'' gene which is associated with oculocerebrorenal syndrome<ref>{{cite web|last1=Reference|first1=Genetics Home|title=OCRL gene|url=https://ghr.nlm.nih.gov/gene/OCRL#conditions|website=Genetics Home Reference|access-date=21 December 2016}}</ref>
<gallery mode="packed" widths="360px" heights="220">
File:NIH 3T3.jpg|Fibroblasts
File:X-linked recessive.svg|X-link recessive inheritance
</gallery>


==Diagnosis==
==Diagnosis==
Line 40: Line 43:


==Treatment==
==Treatment==
[[File:Potassium citrate structure.svg|thumb|150 px|[[Potassium citrate]]]]
[[File:Potassium citrate structure.svg|thumb|250 px|[[Potassium citrate]]]]
In terms of treatment of oculocerebrorenal syndrome for those individuals who are affected by this condition includes the following:<ref name="orp">{{cite web|last1=RESERVED|first1=INSERM US14 -- ALL RIGHTS|title=Orphanet: Oculocerebrorenal syndrome of Lowe|url=http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=534|website=www.orpha.net|access-date=21 December 2016}}</ref>
In terms of treatment of oculocerebrorenal syndrome for those individuals who are affected by this condition includes the following:<ref name="orp">{{cite web|last1=RESERVED|first1=INSERM US14 -- ALL RIGHTS|title=Orphanet: Oculocerebrorenal syndrome of Lowe|url=http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=534|website=www.orpha.net|access-date=21 December 2016}}</ref>
* [[Glaucoma]] control (via medication)
* [[Glaucoma]] control (via medication)
Line 49: Line 52:


==Epidemiology==
==Epidemiology==
Because oculocerebrorenal syndrome is an [[X-linked recessive]] condition, the disease develops mostly in men with very rare occurrences in women, while women are carriers of the disease; it has an estimated prevalence of 1 in 500,000 people.<ref>{{cite journal | author = Loi M | year = 2006 | title = Lowe Syndrome | journal = Orphanet Journal of Rare Diseases | volume = 1 | page = 16 | doi=10.1186/1750-1172-1-16| pmid = 16722554 | pmc = 1526415 }}</ref>
Because oculocerebrorenal syndrome is an [[X-linked recessive]] condition, the disease develops mostly in men with very rare occurrences in women, while women are carriers of the disease; it has an estimated prevalence of 1 in 500,000 people.<ref>{{cite journal | author = Loi M | year = 2006 | title = Lowe Syndrome | journal = Orphanet Journal of Rare Diseases | volume = 1 | page = 16 | doi=10.1186/1750-1172-1-16| pmid = 16722554 | pmc = 1526415 | doi-access = free }}</ref>


==History==
==History==
Line 65: Line 68:
== External links ==
== External links ==
{{Medical resources
{{Medical resources
| DiseasesDB = 29146
| DiseasesDB = 29146
| ICD10 = {{ICD10|E|72|0|e|70}}
| ICD10 = {{ICD10|E|72|0|e|70}}
| ICD9 = {{ICD9|270.8}}
| ICD9 = {{ICD9|270.8}}
| ICDO =
| ICDO =
| OMIM = 309000
| OMIM = 309000
| MedlinePlus =
| MedlinePlus =
| eMedicineSubj = oph
| eMedicineSubj = oph
| eMedicineTopic = 516
| eMedicineTopic = 516
| MeshID = D009800
| MeshID = D009800
| GeneReviewsNBK = NBK1480
| GeneReviewsNBK = NBK1480
| GeneReviewsName = Lowe Syndrome
| GeneReviewsName = Lowe Syndrome
Line 81: Line 84:
{{Amino acid metabolic pathology}}
{{Amino acid metabolic pathology}}
{{X-linked disorders}}
{{X-linked disorders}}
{{Authority control}}


[[Category:Amino acid metabolism disorders]]
[[Category:Amino acid metabolism disorders]]
[[Category:X-linked recessive disorders]]
[[Category:X-linked recessive disorders]]
[[Category:Syndromes affecting the eyes]]
[[Category:Syndromes affecting the eye]]
[[Category:Syndromes affecting the kidneys]]
[[Category:Syndromes affecting the kidneys]]

Latest revision as of 06:19, 16 November 2023

Oculocerebrorenal syndrome
Other namesLowe syndrome
Infant with oculocerebrorenal syndrome
SpecialtyObstetrics and gynaecology, urology, neurology, medical genetics, endocrinology Edit this on Wikidata
SymptomsCataracts[1]
CausesMutations in OCRL gene[1]
Diagnostic methodMRI, urinalysis[2]
TreatmentPhysical therapy, clomipramine[3]

Oculocerebrorenal syndrome (also called Lowe syndrome) is a rare X-linked recessive disorder characterized by congenital cataracts, hypotonia, intellectual disability, proximal tubular acidosis, aminoaciduria and low-molecular-weight proteinuria. Lowe syndrome can be considered a cause of Fanconi syndrome (bicarbonaturia, renal tubular acidosis, potassium loss and sodium loss[4]).[5][6]

Signs and symptoms

[edit]

Boys with Lowe syndrome are born with cataracts in both eyes; glaucoma is present in about half of the individuals with Lowe syndrome, though usually not at birth. While not present at birth, kidney problems develop in many affected boys at about one year of age.[1] Renal pathology is characterized by an abnormal loss of certain substances into the urine, including bicarbonate, sodium, potassium, amino acids, organic acids, albumin, calcium and L-carnitine. This problem is known as Fanconi-type renal tubular dysfunction.[medical citation needed]

Genetics

[edit]

This syndrome is caused by mutations in the OCRL gene which encodes an inositol polyphosphate-5-phosphatase. At least one mechanism by which these mutations cause this syndrome is by loss of its Rab-binding domain.[7][8]

This protein is associated with the primary cilia of the retinal pigment epithelial cells, fibroblasts and kidney tubular cells. This suggests that this syndrome is due to dysfunction of the cilia in these cells.[8] About 120 mutations are associated with this condition and OCRL gene which is associated with oculocerebrorenal syndrome[9]

Diagnosis

[edit]

Diagnosis of oculocerebrorenal syndrome can be done via genetic testing[10] Among the different investigations that can de done are:[2]

Treatment

[edit]
Potassium citrate

In terms of treatment of oculocerebrorenal syndrome for those individuals who are affected by this condition includes the following:[3]

Epidemiology

[edit]

Because oculocerebrorenal syndrome is an X-linked recessive condition, the disease develops mostly in men with very rare occurrences in women, while women are carriers of the disease; it has an estimated prevalence of 1 in 500,000 people.[11]

History

[edit]

It was first described in 1952 by American paediatrician Charles Upton Lowe (August 24, 1921 – February 9, 2012)[12][13] and colleagues at the Massachusetts General Hospital in Boston.[14] Because of the three major organ systems involved (eyes, brain and kidney), it is known as oculocerebrorenal syndrome.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d "Oculocerebrorenal Syndrome: Background, Pathophysiology, Epidemiology". 2016-06-01. {{cite journal}}: Cite journal requires |journal= (help)
  2. ^ a b "Lowe's (Oculo-Cerebro-Renal) Syndrome | Doctor | Patient". Patient. Retrieved 21 December 2016.
  3. ^ a b RESERVED, INSERM US14 -- ALL RIGHTS. "Orphanet: Oculocerebrorenal syndrome of Lowe". www.orpha.net. Retrieved 21 December 2016.{{cite web}}: CS1 maint: numeric names: authors list (link)
  4. ^ "Fanconi syndrome: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2016-12-21.
  5. ^ Lewis, Richard Alan; Nussbaum, Robert L.; Brewer, Eileen D. (1993-01-01). "Lowe Syndrome". In Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora J.H.; Bird, Thomas D.; Fong, Chin-To; Mefford, Heather C. (eds.). GeneReviews. Seattle (WA): University of Washington, Seattle. PMID 20301653.update 2012
  6. ^ "OMIM Entry - # 309000 - LOWE OCULOCEREBRORENAL SYNDROME; OCRL". omim.org. Retrieved 21 December 2016.
  7. ^ Hagemann, Nina; Hou, Xiaomin; Goody, Roger S.; Itzen, Aymelt; Erdmann, Kai S. (2017-06-01). "Crystal structure of the Rab binding domain of OCRL1 in complex with Rab8 and functional implications of the OCRL1/Rab8 module for Lowe syndrome". Small GTPases. 3 (2): 107–110. doi:10.4161/sgtp.19380. ISSN 2154-1256. PMID 22790198.
  8. ^ a b Reference, Genetics Home. "Lowe syndrome". Genetics Home Reference. Retrieved 21 December 2016.
  9. ^ Reference, Genetics Home. "OCRL gene". Genetics Home Reference. Retrieved 21 December 2016.
  10. ^ "Lowe syndrome - Conditions - GTR - NCBI". www.ncbi.nlm.nih.gov. Retrieved 21 December 2016.
  11. ^ Loi M (2006). "Lowe Syndrome". Orphanet Journal of Rare Diseases. 1: 16. doi:10.1186/1750-1172-1-16. PMC 1526415. PMID 16722554.
  12. ^ Kelly, Evelyn B. (2013). Encyclopedia of human genetics and disease. Santa Barbara, Calif.: Greenwood. ISBN 9780313387142. Retrieved 21 December 2016.
  13. ^ Loring, David W.; Bowden, Stephen (2015). INS Dictionary of Neuropsychology and Clinical Neurosciences. Oxford University Press, Incorporated. ISBN 9780195366457. Retrieved 21 December 2016.
  14. ^ Lowe CU, Terrey M, MacLachlan EA (1952). "Organic-aciduria, decreased renal ammonia production, hydrophthalmos, and mental retardation; a clinical entity". American Journal of Diseases of Children. 83 (2): 164–84. doi:10.1001/archpedi.1952.02040060030004. PMID 14884753.

Further reading

[edit]
[edit]